# About CJC-1295 Meds: An Editorial Reading Desk for the CJC-1295 Literature

> CJC-1295 Meds is an independent editorial project that publishes plain-language summaries of the peer-reviewed CJC-1295 research literature. Not a clinic. Not a vendor. Not a prescription.

An independent editorial reading desk for the peer-reviewed CJC-1295 research literature.

## What this site is

CJC-1295 Meds is an independent editorial project that publishes plain-language summaries of the peer-reviewed research literature on CJC-1295 — the synthetic GHRH analog characterized by Teichman et al. in 2006 and its associated with-DAC and no-DAC variants. The site reads as a shader-lit research digest: every section is structured around the underlying study, every quantitative claim ties to a numbered citation, and every page exists to translate the published record into something a careful general reader can follow.

We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. We do not write prescriptions. Our work is editorial commentary on publicly available science.

## What 'meds' means in the domain name

The 'meds' modifier in cjc1295meds.com is editorial framing — a position the publisher occupies relative to the research literature, not a claim about services this site offers. CJC-1295 is not FDA-approved as a medication; it is a research compound with a small primary-source footprint and a sprawling commercial-search landscape. Treating the substance with the rigor it would receive in a real research-pharmacology reference — citation-forward, mechanism-first, dose-and-half-life-precise — is what 'meds' signals here. It is not an offer to provide medical products.

## Editorial standards

Every quantitative claim on this site cites a study in the references index. Every page is built from peer-reviewed primary sources or named federal regulatory documents — Teichman 2006 in the Journal of Clinical Endocrinology & Metabolism, Alba 2006 in the American Journal of Physiology - Endocrinology and Metabolism, Coy 1994 in JCEM, Raun 1998 in the European Journal of Endocrinology, the FDA's 2024 Pharmacy Compounding Advisory Committee briefing, the WADA Prohibited List, and the small set of analytical-chemistry detection papers that anchor the anti-doping literature. We do not write claims that cannot be cited. We do not extrapolate clinical recommendations from preclinical or observational data. We do not endorse the compound, recommend its use, or rank vendors.

## What the shader-lit register is doing

The visual register of this site — dark ink ground, cyan and magenta accent rules, mono shader-debug eyebrows, polished chrome image vocabulary — is a deliberate departure from the warm clinic-marketing tone that dominates the CJC-1295 search landscape. The intent is to mark this site as a research reference rather than a sales surface. The aesthetic vocabulary draws from contemporary motion-design studios (Active Theory, Studio Tendril, Field.io) rather than from pharmaceutical marketing or wellness branding. Same content discipline as a textbook. Different visual register.

---

A shader-lit reading of the published CJC-1295 record — telemetry from the literature, debug-frame editorial, not a clinic and not a prescription.